Chimeric Therapeutics Limited
CHMMF
Other OTC0.10
USD
- -
- -
ISIN
AU0000121576
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-92.00
76.60
5Y
-98.46
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rebecca McQualter
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 62 Lygon Street Carlton VIC Australia 3053
- IPO Date
- Nov 30, 2022
- Website
- chimerictherapeutics.com
- Similar Companies
- Business
- Chimeric Therapeutics Limited (CHM.AX; CHMMF) is an Australian clinical-stage biotechnology company focused on the discovery, development, and commercialization of cell therapies for oncology patients. The company offers a diversified portfolio of autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies targeting solid tumors and hematologic malignancies, including CHM 1101 (CLTX CAR-T) for glioblastoma and other solid tumors; CHM 2101 (CDH17 CAR-T), a third-generation therapy for gastrointestinal cancers such as colorectal, gastric, and neuroendocrine tumors; CHM 0201 (CORE-NK), an off-the-shelf universal donor NK cell therapy for acute myeloid leukemia (AML) and other indications; and preclinical assets like CHM 1301 for pancreatic and ovarian cancers. Founded in 2020 and headquartered at 62 Lygon Street, Carlton, Australia, Chimeric Therapeutics operates primarily in Australia and the United States, with clinical trials conducted at leading institutions including the University of Texas MD Anderson Cancer Center and in collaboration with Case Western Reserve University. Recent developments include US Food and Drug Administration (FDA) clearance for investigational new drug applications for CHM 2101 and fast-track designation for CHM CDH17 in gastroenteropancreatic neuroendocrine tumors; ethics approval and initiation of multi-site Phase 1/2 trials for CHM CDH17 in advanced gastrointestinal cancers; dosing of the first patient in the Phase 1B ADVENT-AML trial evaluating CHM 0201 in combination with standard-of-care for newly diagnosed AML; completion of good manufacturing practice testing to support AML trials; a US patent allowance for CHM 0201 technology; positive Phase 1A data from CHM 1101 in glioblastoma; and promising in vitro data for CHM 1301 in pancreatic and ovarian cancers. In 2025, the company launched a A$3.2 million non-renounceable entitlement offer to fund ongoing CHM CDH17 Phase 1/2 trials and CORE-NK program advancement; entered a manufacturing partnership with Cell Therapies Pty Ltd, Australia's only commercial-scale cell therapy facility, to produce CAR-T and NK cells locally; and formed a collaboration with WuXi ATU for CAR-T development.
Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
Imugene secures FDA backing for Azer-cel registration pathway
Kairos Minerals secures mining agreement with Nyamal Aboriginal Corporation for Mt York Gold Project
Chimeric Therapeutics receives $4.5 million R&D tax incentive refund
Altech draws interest from top-tier battery manufacturer as Silumina Anodes™ hit 1,000-cycle mark
Vaultz completes Xapo Bank onboarding